Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 5/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | SLC1A5 | Q15758 | 9/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741941 | 1.00 | ARG1 (0.43) | ARG1FPR2DPP8DPP9DPP7 | |
| SCHEMBL17690537 | 0.92 | FPR2 (0.36) | ARG1FPR2DPP8DPP9DPP7 | |
| SCHEMBL1741950 | 0.91 | ARG1 (0.39) | ARG1FPR2DPP8DPP9DPP7 | |
| SCHEMBL15501036 | 0.91 | ARG1 (0.39) | ARG1FPR2DPP8DPP9DPP7 | |
| SCHEMBL1741957 | 0.91 | ARG1 (0.39) | ARG1FPR2DPP8DPP9DPP7 | |
| SCHEMBL13339890 | 0.85 | ARG1 (0.34) | ARG1FPR2 | |
| SCHEMBL15501038 | 0.85 | ARG1 (0.50) | ARG1FPR2DPP8DPP9DPP7 | |
| SCHEMBL2838808 | 0.85 | ARG1 (0.50) | ARG1FPR2DPP8DPP9DPP7 | |
| SCHEMBL13233388 | 0.85 | ARG1 (0.50) | ARG1FPR2DPP8DPP9DPP7 | |
| SCHEMBL18079522 | 0.84 | FPR2 (0.37) | FPR2CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3939972-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | Molecular Insight Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3545978-B1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3545978-B1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2021-09-08 | — | — | EP | disclosed |
| US-10898598-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3545978-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | Molecular Insight Pharmaceuticals, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3545978-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | Molecular Insight Pharmaceuticals, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| US-8562945-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8211401-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2389361-A2 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| EP-2373621-A2 | TECHNETIUM-AND RHENIUM-BIS(HETEROARYL)COMPLEXES AND METHODS OF USE THEREOF | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2010065902-A2 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065899-A2 | TECHNETIUM-AND RHENIUM-BIS(HETEROARYL)COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | PSMA1, PSMA5, PSMA3 | ARG1 1276/4885FPR2 4575/4885DPP8 1007/4885 |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | ARG1 435/4885FPR2 2312/4885DPP8 1972/4885 |
| US-10898598-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | ARG1 435/4885FPR2 2312/4885DPP8 1972/4885 |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | ARG1 435/4885FPR2 2312/4885DPP8 1972/4885 |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | SSTR5, SSTR3, SSTR4 | ARG1 170/4885FPR2 1076/4885DPP8 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.